US-based biotechnology company Cynvenio Biosystems has closed a $25.5m series B round led by healthcare company Livzon Pharmaceutical, and featuring Greenwoods Private Equity Funds, Syno Capital as well as unnamed investors.
Founded in 2008, Cynvenio has developed a platform dubbed LiquidBiopsy, which is able to identify rare cancer cells from a standard blood test. The series B funding will support clinical development and commercialisation of treatments.
The company is in the process of setting up a joint venture in China…
